Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 20/20 | 0.62 |
| ▸ | PDE4A | P27815 | 3/20 | 0.61 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20463312 | 0.94 | PDE4B (0.58) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4269812 | 0.88 | PDE4B (0.62) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1031663 | 0.88 | CA12 (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL30575456 | 0.88 | CA12 (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL831072 | 0.87 | PDE4B (0.54) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL1030016 | 0.87 | PDE4B (0.61) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL4278555 | 0.87 | PDE4B (0.63) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL20463319 | 0.85 | PDE4B (0.51) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL22991970 | 0.85 | PDE4B (0.67) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL22713915 | 0.85 | PDE4B (0.65) | PDE4BPDE4APDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-7061978-A | — | — | None | — | — | JP | disclosed |
| EP-3777979-B1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| EP-3777979-B1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | E NITIATE BIOPHARMACEUTICALS HANGZHOU CO LTD (CN) | 2024-01-17 | — | — | EP | disclosed |
| CN-110305072-B | Compounds with phosphodiesterase 4D and acid sphingomyelinase inhibitory activity and uses thereof | 中国药科大学 | 2023-09-19 | — | — | CN | disclosed |
| CN-110407741-B | Anti-inflammatory compound and preparation and application thereof | 启元生物(杭州)有限公司 | 2023-03-21 | — | — | CN | disclosed |
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd. (CN) | 2022-09-13 | — | — | US | disclosed |
| EP-3777979-A1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | Vivavision Biotech, Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| EP-3777979-A1 | ANTI-INFLAMMATORY COMPOUND AND PREPARATION AND USE THEREOF | Vivavision Biotech, Inc. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | VIVAVISION BIOTECH, INC. (CN) | 2020-12-03 | — | — | US | disclosed |
| US-6011060-A | TREATING A DISEASE MEDIATED BY ACTIVATION OF THE TUMOR NECROSIS FACTOR | SCHERING AKTIENGESELLSCHAFT (DE) | 2000-01-04 | — | — | US | disclosed |
| US-5998453-A | ANTIINFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 1999-12-07 | — | — | US | disclosed |
| EP-0928789-A1 | 6-PHENYLTETRAHYDRO-1,3-OXAZIN-2-ONE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME | Nikken Chemicals Company, Limited (JP) | 1999-07-14 | — | — | EP | disclosed |
| US-5783591-A | Administration of oxazolidinone and pyrolidinone compounds for the treatment of inflammation | SCHERING AKTIENGESELLSCHAFT (DE) | 1998-07-21 | — | — | US | disclosed |
| JP-H0761978-A | OXAZOLIDINONE DERIVATIVE | SCHERING AG | 1995-03-07 | — | — | JP | disclosed |
| EP-0550576-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1993-07-14 | — | — | EP | disclosed |
| WO-1992006085-A1 | PHENYLPYRIDINOL DERIVATIVES AS MEDICAMENTS | SMITH KLINE & FRENCH LABORATORIES LIMITED (GB) | 1992-04-16 | — | — | WO | disclosed |
| EP-0198919-B1 | PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT (DE) | 1990-02-28 | — | — | EP | disclosed |
| EP-0198919-A1 | PHARMACEUTICAL PREPARATIONS. | SCHERING AG (DE) | 1986-10-29 | — | — | EP | disclosed |
| WO-1986002268-A1 | PHARMACEUTICAL PREPARATIONS | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1986-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11440886-B2 | Anti-inflammatory compound, and preparation and use thereof | PDE4B, PDE4A, PDE7A | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
| US-20200377460-A1 | ANTI-INFLAMMATORY COMPOUND, AND PREPARATION AND USE THEREOF | PDE4B, PDE4A, PDE7A | PDE4B 1/4885PDE4A 2/4885PDE4C 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.